Results

Deciphera Pharmaceuticals Inc.

01/06/2020 | Press release | Distributed by Public on 01/06/2020 06:19

Deciphera Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 6, 2020-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 11:00 AM PT in San Francisco.

A live webcast of the event will be available on the 'Events and Presentations' page in the 'Investors' section of the Company's website at https://investors.deciphera.com/news-events/events-presentations. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule product candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a 'switched off' or inactivated conformation. These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, and agents designed to inhibit reprogramming of cancer cell metabolism. We have used our platform to develop a diverse pipeline of tumor-targeted, immuno-targeted, and metabolism-targeted product candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200106005295/en/

Source: Deciphera Pharmaceuticals, Inc.

Investor Relations:
Jen Robinson
Deciphera Pharmaceuticals, Inc
[email protected]
781-906-1112

Media:
David Rosen
Argot Partners
[email protected]
212-600-1902